Takeda Pharmaceutical Company has announced that GEMINI II pivotal Phase III trial of vedolizumab in moderately to severely active Crohn’s disease patients has met primary endpoints. The trial evaluated vedolizumab in 1,115 Crohn’s disease patients who have failed at least one conventional therapy, including TNFa antagonists. Takeda General Medicine (Gastrointestinal and Genitourinary) vice president Asit Parikh said, “People living with moderately to severely active Crohn’s disease currently have few treatment options to help them manage their disease.”
